Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality

Journal of Urology

Volumn 187, Issue 6, 2012, Pages 2068-2073

  Tseng, Yolanda D ^a   Chen, Ming Hui ^d   Beard, Clair J ^b,c   Martin, Neil E ^b,c   Orio, Peter F ^b,c   Loffredo, Marian ^b   Renshaw, Andrew A ^e   Choueiri, Toni K ^b,c   Hu, Jim C ^b,c   Kantoff, Philip W ^b,c   D'Amico, Anthony V ^b,c   Nguyen, Paul L ^b,c  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e BAPTIST HOSPITAL OF MIAMI   (United States)

Author keywords

mortality; prostate; prostate specific antigen; prostatic neoplasms; radiotherapy

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADULT COMORBIDITY EVALUATION 27 SCORE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861095171     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.01.073     Document Type: Article

References (17)

1. C.R. Pound, A.W. Partin, M.A. Eisenberger Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591
2. W.R. Lee, A.L. Hanlon, G.E. Hanks Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival J Urol 156 1996 450
3. L.L. Kestin, F.A. Vicini, E.L. Ziaja Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy Cancer 86 1999 1557
4. A.L. Hanlon, H. Diratzouian, G.E. Hanks Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer Int J Radiat Oncol Biol Phys 53 2002 297
5. D.S. Lamb, J.W. Denham, D. Joseph A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial Int J Radiat Oncol Biol Phys 79 2011 385
6. M.E. Ray, H.D. Thames, L.B. Levy PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis Int J Radiat Oncol Biol Phys 64 2006 1140
7. P. Alcantara, A. Hanlon, M.K. Buyyounouski Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death Cancer 109 2007 41
8. A.V. D'Amico, J. Manola, M. Loffredo 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 292 2004 821
9. A.V. D'Amico, M.H. Chen, A.A. Renshaw Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death Int J Radiat Oncol Biol Phys 75 2009 10
10. E.L. Kaplan, P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457
11. I.F. Tannock, R. de Wit, W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502
12. P.W. Kantoff, C.S. Higano, N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411
13. J.S. de Bono, C.J. Logothetis, A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995
14. A.V. D'Amico, J.W. Moul, P.R. Carroll Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 95 2003 1376
15. H.M. Sandler, M.L. DeSilvio Surrogate end points for prostate cancer: what is the prostate-specific antigen telling us? J Natl Cancer Inst 95 2003 1352
16. M.E. Ray, K. Bae, M.H. Hussain Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial J Natl Cancer Inst 101 2009 228
17. J.W. Denham, A. Steigler, C. Wilcox Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer 115 2009 4477